Literature DB >> 33462791

HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil.

Sérgio Monteiro de Almeida1, Indianara Rotta2, Luine Rosele Renaud Vidal2, Jucelia Stadinicki Dos Santos2, Avindra Nath3, Kory Johnson3, Scott Letendre4, Ronald J Ellis4.   

Abstract

The transactivator of transcription (Tat) is a key HIV regulatory protein. We aimed to identify the frequency of key polymorphisms in HIV-1C compared with HIV-1B Tat protein, chiefly in the cysteine-, arginine-, and glutamine-rich domains and identify novel point mutations in HIV-1B and C sequences from Southern Brazil. This study was the first to investigate the genetic diversity and point mutations within HIV-1 Tat C in a Brazilian cohort. This was an observational, cross-sectional study, which included sequences of HIV-1B (n = 20) and HIV-1C (n = 21) from Southern Brazil. Additionally, 344 HIV-1C sequences were obtained from the Los Alamos database: 29 from Brazil and 315 from Africa, Asia, and Europe. The frequency of C31S substitution on HIV-1 Tat C in Brazil was 82% vs. 10% in the HIV-1B group (p < 0.0001). The frequency of the R57S substitution among the HIV-1C sequences from Brazil was 74% vs. 20% in HIV-1B (p = 0.004), and that of substitution Q63E in HIV-1C was 80% and 20% in HIV-1B (p < 0.0001). The mutation P60Q was more frequent in HIV-1B than in HIV-1C (55% and 6.12%, respectively, p < 0.0001)). Novel point mutations in the HIV-1C and B Tat functional domains were described. The frequency of C31S and other key point mutations in HIV-1 Tat C in Brazil were similar to those described in Africa, although lower than those in India. The Tat-B and C sequences found in Southern Brazil are consistent with biological differences and have potential implications for HIV-1 subtype pathogenesis.

Entities:  

Keywords:  Dicysteine; HIV-1; Neuropathogenesis; Polymorphism; Subtype C; Tat

Mesh:

Substances:

Year:  2021        PMID: 33462791      PMCID: PMC8510567          DOI: 10.1007/s13365-020-00935-z

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  53 in total

1.  HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes.

Authors:  I W Park; J F Wang; J E Groopman
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

2.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

3.  Structural and functional characterization of human immunodeficiency virus tat protein.

Authors:  S Ruben; A Perkins; R Purcell; K Joung; R Sia; R Burghoff; W A Haseltine; C A Rosen
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity.

Authors:  D S Magnuson; B E Knudsen; J D Geiger; R M Brownstone; A Nath
Journal:  Ann Neurol       Date:  1995-03       Impact factor: 10.422

5.  Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity.

Authors:  C J Beall; S Mahajan; D E Kuhn; P E Kolattukudy
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

6.  Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02_AG (CRF02_AG) has a higher in vitro replicative capacity than its parental subtypes A and G.

Authors:  Frank A J Konings; Sherri T Burda; Mateusz M Urbanski; Ping Zhong; Arthur Nadas; Phillipe N Nyambi
Journal:  J Med Virol       Date:  2006-05       Impact factor: 2.327

7.  Intracellular analysis of in vitro modified HIV Tat protein.

Authors:  S E Koken; A E Greijer; K Verhoef; J van Wamel; A G Bukrinskaya; B Berkhout
Journal:  J Biol Chem       Date:  1994-03-18       Impact factor: 5.157

8.  Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy.

Authors:  B Prabhakar; Asima Banu; H B Pavithra; P Chandrashekhara; Suresh Sasthri
Journal:  Indian J Sex Transm Dis AIDS       Date:  2011-07

9.  Evolutionary Dynamics of Tat in HIV-1 Subtypes B and C.

Authors:  Chandra Nath Roy; Irona Khandaker; Hitoshi Oshitani
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

10.  Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.

Authors:  Filippo Canducci; Maria Chiara Marinozzi; Michela Sampaolo; Stefano Berrè; Patrizia Bagnarelli; Massimo Degano; Giulia Gallotta; Benedetta Mazzi; Philippe Lemey; Roberto Burioni; Massimo Clementi
Journal:  Retrovirology       Date:  2009-01-15       Impact factor: 4.602

View more
  3 in total

1.  Molecular Modeling of Subtype-Specific Tat Protein Signatures to Predict Tat-TAR Interactions That May Be Involved in HIV-Associated Neurocognitive Disorders.

Authors:  Monray E Williams; Ruben Cloete
Journal:  Front Microbiol       Date:  2022-04-07       Impact factor: 5.640

Review 2.  Multiple Receptors Involved in Invasion and Neuropathogenicity of Canine Distemper Virus: A Review.

Authors:  Jianjun Zhao; Yanrong Ren
Journal:  Viruses       Date:  2022-07-12       Impact factor: 5.818

Review 3.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.